FDA Drug Approvals, Newly Elected Board of Directors, and Stock Price Updates... -- NEW YORK, December 25, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Theravance Inc. (NASDAQ: THRX), Quintiles Transnational Holdings Inc. (NYSE: Q), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Immunomedics Inc. Theravance Inc. On December 18, 2013, Theravance Inc. (Theravance), along with GlaxoSmithKline, announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA as a combination anticholinergic/long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The Company stated that Anoro Ellipta is the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of COPD, and is not indicated for the relief of acute bronchospasm or for the treatment of asthma. Commenting on the approval, Rick E. Winningham, CEO of Theravance said, "We are very pleased that Anoro Ellipta has become the first once-daily dual bronchodilator approved in the US for the treatment of COPD. This is a significant milestone for Theravance and GSK and is testament to our ongoing partnership and shared commitment to the development of respiratory medicines. The Full Research Report on Theravance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Quintiles Transnational Holdings Inc. On December 17, 2013, Quintiles Transnational Holdings Inc. (Quintiles) announced the election of Mr. Richard Relyea to its Board of Directors. The Company stated that Relyea was designated by equity investor 3i to fill a vacancy on its Board of Directors, and came as the result of Denis Ribon's pending departure from 3i and resulting resignation from the Quintiles board. Pursuant to the Quintiles shareholders agreement, 3i retains the right to designate a replacement to the board. The Company also mentioned that prior to the Quintiles IPO, Relyea served as 3i's observer to the Quintiles board. The Full Research Report on Quintiles Transnational Holdings Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Ironwood Pharmaceuticals Inc. On December 20, 2013, Ironwood Pharmaceuticals Inc.'s (Ironwood Pharmaceuticals) stock rose 4.63%, ending the day at $11.76. Over the previous three trading sessions, shares of Ironwood Pharmaceuticals gained 10.11% compared to the Nasdaq Composite which gained 2.01% during the same period. The Full Research Report on Ironwood Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Progenics Pharmaceuticals Inc. On December 20, 2013, Progenics Pharmaceuticals Inc.'s (Progenics Pharmaceuticals) stock rose 4.87%, ending the day at $5.17. Over the previous three trading sessions, shares of Progenics Pharmaceuticals increased 12.64%, significantly beating the Nasdaq Composite which increased 2.01% during the same period. The Full Research Report on Progenics Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: Immunomedics Inc. On December 20, 2013, Immunomedics Inc.'s (Immunomedics) stock rose 3.38%, ending the day at $4.28. Over the previous three trading sessions, shares of Immunomedics increased 4.90% compared to the Nasdaq Composite which increased 2.01% during the same period. The Full Research Report on Immunomedics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: